SEI Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.07M | Buy |
211,833
+119,739
| +130% | +$2.97M | 0.01% | 1300 |
|
|
2026
Q1 | $1.93M | Sell |
92,094
-61,632
| -40% | -$1.39M | ﹤0.01% | 2028 |
|
|
2025
Q4 | $3.54M | Sell |
153,726
-36,736
| -19% | -$1.21M | ﹤0.01% | 1551 |
|
|
2025
Q3 | $5.73M | Buy |
190,462
+100,270
| +111% | +$3.01M | 0.01% | 1247 |
|
|
2025
Q2 | $3.28M | Sell |
90,192
-22,022
| -20% | -$794K | ﹤0.01% | 1440 |
|
|
2025
Q1 | $4.06M | Buy |
112,214
+13,905
| +14% | +$578K | 0.01% | 1349 |
|
|
2024
Q4 | $4.14M | Sell |
98,309
-17,828
| -15% | -$884K | 0.01% | 1385 |
|
|
2024
Q3 | $6.45M | Buy |
116,137
+24,338
| +27% | +$1.24M | 0.01% | 1177 |
|
|
2024
Q2 | $3.77M | Buy |
91,799
+25,803
| +39% | +$1.1M | 0.01% | 1348 |
|
|
2024
Q1 | $3.08M | Buy |
65,996
+616
| +0.9% | +$29.1K | ﹤0.01% | 1423 |
|
|
2023
Q4 | $3.13M | Buy |
65,380
+9,828
| +18% | +$381K | 0.01% | 1401 |
|
|
2023
Q3 | $1.98M | Sell |
55,552
-10,202
| -16% | -$404K | ﹤0.01% | 1604 |
|
|
2023
Q2 | $3.03M | Buy |
65,754
+8,904
| +16% | +$413K | 0.01% | 1451 |
|
|
2023
Q1 | $2.28M | Sell |
56,850
-12,256
| -18% | -$526K | ﹤0.01% | 1559 |
|
|
2022
Q4 | $3.2M | Buy |
69,106
+14,199
| +26% | +$558K | 0.01% | 1250 |
|
|
2022
Q3 | $2.27M | Buy |
54,907
+26,938
| +96% | +$1.38M | 0.01% | 1486 |
|
|
2022
Q2 | $1.66M | Buy |
27,969
+1,899
| +7% | +$117K | ﹤0.01% | 1640 |
|
|
2022
Q1 | $1.89M | Buy |
26,070
+22,267
| +586% | +$1.55M | ﹤0.01% | 1555 |
|
|
2021
Q4 | $320K | Buy |
+3,803
| New | +$309K | ﹤0.01% | 2310 |
|
|
2021
Q2 | – | Sell |
-14,737
| Closed | -$1.98M | – | 2617 |
|
|
2021
Q1 | $1.98M | Sell |
14,737
-20
| -0.1% | -$2.72K | 0.01% | 1457 |
|
|
2020
Q4 | $2.04M | Sell |
14,757
-8,303
| -36% | -$985K | 0.01% | 1381 |
|
|
2020
Q3 | $1.9M | Sell |
23,060
-11,727
| -34% | -$972K | 0.01% | 1314 |
|
|
2020
Q2 | $2.72M | Sell |
34,787
-4,845
| -12% | -$321K | 0.01% | 1129 |
|
|
2020
Q1 | $1.76M | Buy |
39,632
+4,542
| +13% | +$236K | 0.01% | 1199 |
|
|
2019
Q4 | $1.5M | Buy |
35,090
+12,684
| +57% | +$523K | ﹤0.01% | 1472 |
|
|
2019
Q3 | $959K | Sell |
22,406
-2,280
| -9% | -$124K | ﹤0.01% | 1618 |
|
|
2019
Q2 | $1.57M | Buy |
24,686
+14,331
| +138% | +$912K | 0.01% | 1432 |
|
|
2019
Q1 | $718K | Buy |
+10,355
| New | +$592K | ﹤0.01% | 1711 |
|
|
2018
Q3 | – | Sell |
-6
| Closed | – | – | 3227 |
|
|
2018
Q2 | $0 | Sell |
6
-3
| -33% | -$194 | ﹤0.01% | 3753 |
|
|
2018
Q1 | $0 | Sell |
9
-2,474
| -100% | -$125K | ﹤0.01% | 3629 |
|
|
2017
Q4 | $115K | Buy |
2,483
+454
| +22% | +$22.3K | ﹤0.01% | 2093 |
|
|
2017
Q3 | $108K | Buy |
2,029
+22
| +1% | +$1.3K | ﹤0.01% | 2058 |
|
|
2017
Q2 | $125K | Buy |
+2,007
| New | +$121K | ﹤0.01% | 2004 |
|
|
2017
Q1 | – | Sell |
-925
| Closed | -$65K | – | 3052 |
|
|
2016
Q4 | $65K | Sell |
925
-226
| -20% | -$16K | ﹤0.01% | 2075 |
|
|
2016
Q3 | $82K | Buy |
1,151
+181
| +19% | +$11.6K | ﹤0.01% | 1924 |
|
|
2016
Q2 | $47K | Buy |
970
+272
| +39% | +$17.6K | ﹤0.01% | 1959 |
|
|
2016
Q1 | $44K | Buy |
698
+624
| +843% | +$40.8K | ﹤0.01% | 1875 |
|
|
2015
Q4 | $9K | Sell |
74
-20,534
| -100% | -$2.05M | ﹤0.01% | 2240 |
|
|
2015
Q3 | $1.99M | Buy |
20,608
+16,843
| +447% | +$1.93M | 0.02% | 801 |
|
|
2015
Q2 | $385K | Buy |
3,765
+120
| +3% | +$9.32K | ﹤0.01% | 1252 |
|
|
2015
Q1 | $226K | Buy |
+3,645
| New | +$202K | ﹤0.01% | 1381 |
|
Other funds holding RARE
RI
FCM
SEI Investments's RARE Position: Q2 2026 in Review
SEI Investments increased its Ultragenyx Pharmaceutical (RARE) stake by 130% in Q2 2026, buying an estimated $2.97M and bringing the position to 211,833 shares worth $7.07M. The position accounts for 0.01% of the portfolio, ranked #1300.
SEI Investments first reported a position in RARE in Q1 2015 and has held it in 41 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- SEI Investments held 211,833 shares of Ultragenyx Pharmaceutical worth $7.07M as of Q2 2026.
- SEI Investments bought 119,739 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $2.97M.
- Ultragenyx Pharmaceutical made up 0.01% of SEI Investments's portfolio in Q2 2026, its #1300 holding.
- SEI Investments first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 41 quarters since.
- 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.